Weight management · Phase 1
AMG 133: first human study
What was tested?
Maridebart cafraglutide, also called AMG 133, versus placebo in an ascending-dose study in people with obesity. ↗
Registered primary question: The number of participants with treatment-emergent adverse events, with observation windows varying by study part. ↗
What the reviewed report found
Journal year 2024 · Article summary reviewed 2026-09-15
The authors reported weight reductions in the early human program alongside pharmacologic and preclinical findings.↗
Keep in context: The paper contains both animal experiments and human observations. Only the human study belongs to this trial card; weight change was not the registered primary safety endpoint. ↗↗
What a closer reading adds
Selected full-text sections checked 2026-09-20. These notes add context to the earlier article summary; they are not a complete risk-of-bias assessment.
Which participants are in this report
The full text describes a reported dataset of 75 participants within a registered study enrolling 110. Additional bioavailability, digital-tool and titration cohorts were outside that dataset. The registry total should not be used as the denominator for every published result. Full text ↗ · Indexed abstract ↗
Sections: Clinical study design.
Exploratory weight findings
Safety and tolerability were primary; body weight was exploratory. The sample size followed early-phase conventions rather than a formal efficacy calculation, and the paper describes post hoc tests. This context matters when interpreting its weight-loss signal. Full text ↗ · Indexed abstract ↗
Sections: AMG 133 clinical study; Clinical outcomes; Statistical analysis for phase 1 clinical study.
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 110 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Quadruple
- Design
- Sequential
- Eligible ages
- 18 Years to 65 Years
- Registry results
- Posted in this snapshot
Registry source ↗ · Updated 2025-12-10; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
Early translational and human program
- Design in the report
- The publication combines preclinical experiments with an early randomized clinical trial.↗
- Participants in the report
- The human trial enrolled people with obesity; animal findings in the same report are not human outcomes.↗
- Limitations
- The abstract does not support a complete participant-flow or harms appraisal. Early exploratory findings cannot establish durable clinical benefit, and the conjugate is not interchangeable with other peptides.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity ↗
Protocol identifier: 20180048. Sponsor: Amgen.
Retrieved 2026-09-20; SHA-256 70f00f3032e9c27fe1160ddda7e00030ce4b6d55ad7ff7e8032fc8a04a92e8ef.
PMID 38316982
Exact trial identity is declared in the article abstract indexed in PubMed. The registry independently labels this reference BACKGROUND. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 38316982. SHA-256 f2177628b98083064df17512c3dd229b760887c00cc64c4cfa4fc4e49523b12a.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 2c0bc8063119ce5e607f80d3408a47d43f817bd158bcb457a2f27dc8b1305e80.
Selected full text: PMC10896721
Retrieved 2026-09-20; SHA-256 478426a0d5db2904b80277b75c031bfc0e86e4d615de08b17435270cb227511c. Section identifiers and hashes are included in the cited study data.